173 related articles for article (PubMed ID: 19251404)
1. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study.
Sipsas NV; Lewis RE; Raad II; Kontoyiannis DP
Int J Antimicrob Agents; 2009 Jul; 34(1):95-8. PubMed ID: 19251404
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
4. Caspofungin for the treatment of candidaemia in patients with haematological malignancies.
Pagano L; Fianchi L; Fanci R; Candoni A; Caira M; Posteraro B; Morselli M; Valentini CG; Farina G; Mitra ME; Offidani M; Sanguinetti M; Tosti ME; Nosari A; Leone G; Viale P
Clin Microbiol Infect; 2010 Mar; 16(3):298-301. PubMed ID: 19549221
[TBL] [Abstract][Full Text] [Related]
5. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
6. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.
Wang E; Farmakiotis D; Yang D; McCue DA; Kantarjian HM; Kontoyiannis DP; Mathisen MS
J Antimicrob Chemother; 2015 Aug; 70(8):2362-8. PubMed ID: 25855759
[TBL] [Abstract][Full Text] [Related]
7. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
[TBL] [Abstract][Full Text] [Related]
8. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil.
Gonçalves SS; Amorim CS; Nucci M; Padovan AC; Briones MR; Melo AS; Colombo AL
Clin Microbiol Infect; 2010 Jul; 16(7):885-7. PubMed ID: 19686280
[TBL] [Abstract][Full Text] [Related]
9. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
Slavin MA; Sorrell TC; Marriott D; Thursky KA; Nguyen Q; Ellis DH; Morrissey CO; Chen SC;
J Antimicrob Chemother; 2010 May; 65(5):1042-51. PubMed ID: 20202987
[TBL] [Abstract][Full Text] [Related]
10. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study.
Torres HA; Kontoyiannis DP; Rolston KV
Support Care Cancer; 2004 Jul; 12(7):511-6. PubMed ID: 14986077
[TBL] [Abstract][Full Text] [Related]
11. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.
Forrest GN; Weekes E; Johnson JK
J Infect; 2008 Feb; 56(2):126-9. PubMed ID: 18082269
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin for the treatment of less common forms of invasive candidiasis.
Cornely OA; Lasso M; Betts R; Klimko N; Vazquez J; Dobb G; Velez J; Williams-Diaz A; Lipka J; Taylor A; Sable C; Kartsonis N
J Antimicrob Chemother; 2007 Aug; 60(2):363-9. PubMed ID: 17526917
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
15. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Hakki M; Staab JF; Marr KA
Antimicrob Agents Chemother; 2006 Jul; 50(7):2522-4. PubMed ID: 16801435
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of an infant infected with refractory C. parapsilosis with caspofungin.
Ozkaya-Parlakay A; Tezer H; Kazmacan T; Gulhan B; Unal S
J Trop Pediatr; 2014 Aug; 60(4):329-30. PubMed ID: 24567311
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
[TBL] [Abstract][Full Text] [Related]
20. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.
Girão E; Levin AS; Basso M; Gobara S; Gomes LB; Medeiros EA; Costa SF
Med Mycol; 2008 Sep; 46(6):581-8. PubMed ID: 19180727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
